Back to Type 2 Diabetes
NCT02577016
NCT02577016
Who may be able to join
Who might be able to join this trial:
- You have been diagnosed with type 2 diabetes
- Your blood sugar is not well controlled through diet, exercise, and a medication called ipragliflozin alone
- Your HbA1c (a blood test that shows your average blood sugar over the past few months) is between 7.0% and 10.0% before the trial starts
Who may not be able to join:
- You have a history of type 1 diabetes or have previously had a dangerous condition called ketoacidosis (a serious complication where the body produces too many acids)
- You have taken certain diabetes medications recently — specifically insulin or thiazolidinediones (a type of diabetes pill) within the past 12 weeks, or a medication called sitagliptin within the past 8 weeks
- You currently have an active urinary tract infection (such as pain when urinating) or a genital infection that is causing you noticeable symptoms
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Completed
Phase
Phase 3
Sponsor
Merck Sharp & Dohme LLC
Registry
clinicaltrials_gov
Start date
5 November 2015
Est. completion
18 November 2016
Primary endpoints
Change From Baseline in HbA1c at Week 24; Percentage of Participants Who Experienced at Least One Adverse Event (AE); Percentage of Participants Who Discontinued Study Drug Due to an AE
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.